Axsome Therapeutics, Inc. $AXSM Stock Holdings Lifted by Aberdeen Group plc

Aberdeen Group plc lifted its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 15.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,648 shares of the company’s stock after acquiring an additional 12,732 shares during the quarter. Aberdeen Group plc owned 0.19% of Axsome Therapeutics worth $11,495,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Axsome Therapeutics by 5.8% during the second quarter. Geode Capital Management LLC now owns 989,453 shares of the company’s stock valued at $103,303,000 after buying an additional 54,600 shares in the last quarter. State Street Corp lifted its position in shares of Axsome Therapeutics by 5.8% in the 2nd quarter. State Street Corp now owns 958,503 shares of the company’s stock valued at $100,058,000 after acquiring an additional 52,483 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Axsome Therapeutics by 41.1% in the 2nd quarter. Bank of America Corp DE now owns 753,429 shares of the company’s stock valued at $78,650,000 after acquiring an additional 219,527 shares in the last quarter. Man Group plc boosted its stake in Axsome Therapeutics by 2.3% in the 2nd quarter. Man Group plc now owns 525,069 shares of the company’s stock worth $54,812,000 after purchasing an additional 11,848 shares during the period. Finally, Norges Bank purchased a new position in Axsome Therapeutics during the 2nd quarter worth approximately $48,889,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 12,000 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total value of $2,255,040.00. Following the transaction, the chief financial officer directly owned 42,588 shares in the company, valued at approximately $8,003,136.96. This trade represents a 21.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark E. Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the sale, the director directly owned 10,002 shares of the company’s stock, valued at $1,652,130.36. This trade represents a 78.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 308,874 shares of company stock worth $51,390,805. 22.30% of the stock is currently owned by company insiders.

Axsome Therapeutics Trading Up 0.8%

Shares of AXSM opened at $186.18 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. The company has a market cap of $9.39 billion, a price-to-earnings ratio of -39.87, a PEG ratio of 11.92 and a beta of 0.40. The stock has a fifty day moving average price of $173.16 and a two-hundred day moving average price of $143.34. Axsome Therapeutics, Inc. has a 52-week low of $86.99 and a 52-week high of $191.50.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on AXSM shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Axsome Therapeutics in a report on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Thursday, January 29th. Robert W. Baird set a $209.00 price target on shares of Axsome Therapeutics in a report on Tuesday, January 13th. Finally, Wells Fargo & Company increased their price objective on Axsome Therapeutics from $157.00 to $193.00 and gave the stock an “overweight” rating in a report on Tuesday, January 13th. Sixteen analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $216.07.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.